TNF and psoriasis: Currently, five anti-TNF biologics and in total 25 drugs that inhibit or modulate the effects of TNF, are approved for clinical use by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA, AS, psoriasis and psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), CD and ulcerative colitis (UC).